Weiss Asset Management LP Acquires 1,846,851 Shares of Cellebrite DI Ltd. $CLBT

Weiss Asset Management LP lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 3,485.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,899,841 shares of the company’s stock after purchasing an additional 1,846,851 shares during the period. Weiss Asset Management LP’s holdings in Cellebrite DI were worth $26,180,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cellebrite DI by 16.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after purchasing an additional 24,881 shares in the last quarter. Geode Capital Management LLC increased its position in Cellebrite DI by 16.2% in the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after buying an additional 43,898 shares in the last quarter. Invesco Ltd. raised its stake in shares of Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after buying an additional 209,473 shares during the period. First Trust Advisors LP bought a new position in shares of Cellebrite DI in the second quarter worth about $341,000. Finally, Marshall Wace LLP purchased a new position in shares of Cellebrite DI during the 2nd quarter valued at about $4,472,000. 45.88% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer owned 590,777 shares of the company’s stock, valued at $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 158,191 shares of company stock worth $2,479,438. 5.70% of the stock is owned by corporate insiders.

Cellebrite DI Stock Up 1.1%

Shares of Cellebrite DI stock opened at $14.22 on Friday. The stock’s 50-day simple moving average is $14.19 and its 200-day simple moving average is $14.31. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of 50.79, a PEG ratio of 1.76 and a beta of 1.17.

Analyst Ratings Changes

CLBT has been the subject of a number of recent research reports. DA Davidson began coverage on Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective for the company. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Finally, Needham & Company LLC dropped their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.